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Abstract: In the last decade a tremendous amount has been learned about the biology and 
treatment of gastrointestinal stromal tumor (GIST). Imatinib mesylate has revolutionized the 
treatment of metastatic GIST. In addition, the role of imatinib in localized GIST has gained 
much interest and may improve patient outcomes. Additionally, research efforts aimed at 
understanding the biology and the molecular heterogeneity of GIST both at initial presentation 
and at the time of resistance to imatinib, has helped guide rational approaches to treatment as 
well as future efforts aimed at treating imatinib-resistant GIST.
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Diagnosis
Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumor 
of the gastrointestinal tract.1 As a distinct disease entity, it is estimated that GIST has 
an annual incidence of around 14.5 per million individuals worldwide.2 The median 
age of onset is ∼60 years old with a small though biologically distinct sub-population 
in the pediatric age group.3,4
Prior to the late 1990s, GIST was a disease poorly understood, whose pathogen-
esis, natural history and even the cell of origin were unclear. In addition, GISTs were 
frequently diagnosed as other entities, which included leiomyosarcoma, leiomyoblas-
toma, bizarre leiomyoma, plexosarcoma and gastrointestinal autonomic nerve tumor 
(GANT) amongst other names.5,6 It was not until the seminal discovery by Hirota 
and colleagues in 1998 that the first clear insights to this disease were gained. In this 
landmark publication, the group reported the finding of activating KIT mutations in 
a significant proportion of GISTs, with constitutive ligand-independent activation of 
the KIT-receptor tyrosine kinase (RTK), and a near universal expression of KIT on 
immunohistochemistry.7 Corroborated by Kindblom and others, it was demonstrated 
that GIST cells were closely related to the interstitial cells of Cajal.8 This understand-
ing provided the platform for accurate and uniform diagnoses of this uncommon 
tumor and the rational development and use of tyrosine kinase inhibitors (TKI) in the 
management of GIST.
Prognostic factors
As it became clearer investigators could reliably identify GIST, research efforts 
were focused on the determination of histological and clinical prognostic factors Biologics: Targets & Therapy 2010:4 20
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for localized GIST. Tumors showing the usual histological 
criteria for malignancy did not uniformly behave aggressively. 
Alternatively, some tumors with typical “benign” features 
gave rise to metastases. Size of tumor and mitotic count 
gained the greatest acceptance of being predictive of 
outcome. Using these two indices, Fletcher and colleagues 
were able to stratify patients with primary GISTs into 
four risk groups predicting for aggressive behavior.9 More 
recently, work from the Armed Forces Institute of Pathology 
detailing their experience with a large population of GIST 
patients identified anatomic location being an important 
predictor of relapse. In this model, which is the current 
accepted risk model for localized GIST, the primary disease 
site together with tumor size and mitotic count provide a 
model for the risk of future recurrence following resection 
of localized disease.10
Imatinib
Imatinib mesylate (Gleevec®; Novartis Oncology) is an 
oral, small molecule tyrosine kinase inhibitor with good 
oral bioavailability.11 Imatinib exhibits potent inhibitory 
activity against KIT, platelet-derived growth factor receptor 
(PDGFR), ABL kinase and the chimeric BCR-ABL fusion 
oncoprotein of chronic myeloid leukemia. The binding of 
the KIT-ligand (stem cell factor) to KIT-RTK results in 
homodimerization and autophosphorylation of the RTK 
with subsequent kinase activation. Phosphorylation of 
specific tyrosine residues on KIT triggers a cascade of 
secondary signaling events and activation of downstream 
pathways. In GIST, tumor cells harbor gain-of-function KIT 
mutations leading to ligand-independent KIT activation. 
Imatinib occupies the ATP-binding pocket of KIT, pre-
venting substrate phosphorylation which in turn inhibits 
downstream signaling, cellular proliferation and cell 
survival (Figure 1).
Historically, management of advanced GIST revolved 
around surgery with few effective systemic therapeutic 
options. Although the efficacy of cytotoxic chemotherapy 
was hard to estimate due to differences in histological clas-
sification, it is clear that despite aggressive combination 
chemotherapy, response rates to treatment are poor, typi-
cally less than 10%.12 Median overall survival for patients 
with metastatic GIST in the pre-TKI era was estimated to be 
between 10 and 20 months.1
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Figure 1 Mechanism of action of imatinib.  A) Under physiological conditions,   ATP binds to KiT or PDGFrA, leading to phosphorylation and autoactivation of the receptor, or 
phosphorylation of substrate molecules resulting in activation of downstream signalling pathways. B) imatinib occupies the ATP-binding pocket of KiT or PDGFA, preventing 
substrate phosphorylation which in turn inhibits downstream signaling, cellular proliferation and cell survival.
reprinted from The Lancet, 369, rubin BP, Heinrich MC, Corless CL. Gastrointestinal stromal tumour. 1731–1741.70 Copyright © 2007, with permission from elsevier.Biologics: Targets & Therapy 2010:4 21
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Management of localized GIST 
in the TKI era
Standard treatment for localized GIST involves complete 
surgical excision. Lymph node dissection is not standard 
practise as tumor spread is typically hematogenous rather than 
through the lymphatic system. If complete surgical resec-
tion with negative margins (R0 resection) is not achieved 
at first attempt and can be safely accomplished by repeat 
surgery, this option may be considered. In cases where 
R0 surgery cannot be achieved due to technical reasons 
or entails significant morbidities, then consideration may 
be given to a peri-operative course of imatinib with aims 
for cytoreduction. This approach was demonstrated to be 
safe and feasible in a Radiation Therapy Oncology Group 
(RTOG)-led prospective non-randomized phase II study. 
In this study 52 analyzable patients with KIT-positive GIST, 
30 with locally advanced disease (defined as tumors 5 cm) 
and 22 with potentially operable recurrent metastatic disease 
(defined as tumors 2 cm) were enrolled and treated with 
imatinib 600 mg/day over a period of 8 to 12 weeks prior to 
definitive surgery. Patients were then treated with imatinib 
for 2 years as postoperative adjuvant treatment.13 Results of 
this study are summarized in Table 1. The peri-operative use 
of imatinib was found to be safe and surgical complications 
were within expectation for this group of patients. In another 
separate study by Fiore and colleagues, exploring the effects 
of pre-operative imatinib in patients with unresectable or 
locally advanced primary GIST, investigators performed 
a single-center retrospective review of 15 patients treated 
with pre-operative imatinib, followed by surgery performed 
at the time of best response.14 Patients continued imatinib 
for a total of 2 years. Responses were graded per response 
evaluation criteria in solid tumors (RECIST) criteria.15 
Median duration of imatinib pre-treatment was 9 months 
(range, 3 to 16 months). Median tumor size prior to imatinib 
was 11 cm. All patients experienced tumor shrinkage, with 
1 (7%) complete radiological response, 73% partial response 
and 20% minor response. Three patients who were initially 
deemed unresectable were sufficiently cyto-reduced to allow 
for complete surgery, while 7 with initial indications for 
extensive surgery underwent conservative resection. Taken 
together, these studies suggest that pre-operative imatinib 
appears to be safe, feasible and is an option for patients with 
primary locally advanced GIST or gross residual disease in 
consideration of repeat surgery, where either a R0 resec-
tion is technically impossible or associated with significant 
functional morbidities. In clinical practice when faced with 
such a clinical situation, we would generally recommend 
patients be initiated on pre-operative imatinib until best 
response, typically at least 3 to 6 months, before proceeding 
to surgery.16 Monitoring with standard computed tomography 
(CT)/magnetic resonance imaging (MRI) is advised as up 
to 10% to 15% of patients may be primarily refractory to 
imatinib and thus a small window of opportunity for cure 
through aggressive surgery may be lost.18 Fluoro-2-deoxy-
D-glucose positron emission tomography (FDG-PET) scan 
may be useful as a rapid assessment of tumor response to aid 
clinical decision making.17 Mutational analysis may also be 
helpful in excluding GIST genotypes known to be insensi-
tive to imatinib.
Although surgery is undertaken with curative intent 
in localized GIST, 40% of patients will relapse and ulti-
mately die of their disease.18 Following the demonstration 
of dramatic sustained anti-tumor activity of imatinib in 
advanced GIST as described below, investigators in North 
America led by the American College of Surgeons Oncology 
Group (ACOSOG) performed a randomized phase III 
placebo-controlled study of adjuvant treatment with imatinib 
following complete surgical resection of primary GIST.19 
Patients had to have tumors of at least 3 cm in size and were 
randomly assigned to post-operative imatinib 400 mg/day or 
placebo for 1 year. The primary endpoint was recurrence-
free survival. Median follow-up was about 20 months. The 
study was closed at the time of the first interim analysis 
after a median follow up of 15 months. At this time point, 
a statistically significant benefit was seen in the imatinib arm 
Table 1 response and clinical outcomes to pre-operative imatinib therapy: results of rTOG 0132/ACriN 6665 study
Locally advanced GIST (N = 30) Recurrent/Metastatic GIST (N = 22)
Partial response 7% 4.5%
Stable disease 83% 91%
Unknown 10% –
Progressive disease – 4.5%
2-year progression-free survival 83% 77%
Note: response grading based on reCiST criteria.Biologics: Targets & Therapy 2010:4 22
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with recurrence-free survival at 1 year reported to be 98% 
in the imatinib arm compared to 83% in the placebo arm. 
A longer follow-up would be required to draw definitive 
conclusions with regards to the absolute delay in relapse, 
overall survival and time to secondary resistance, however 
the study was not designed to capture these endpoints. Based 
on the results of the ACOSOG trial, the US Food and Drug 
Administration (FDA) and European Medicines Agency 
(EMEA) approved the use of imatinib following complete 
resection of GIST. Two additional studies in Europe are 
ongoing to further evaluate the potential benefit of adju-
vant imatinib. The European Organization of Research and 
Treatment of Cancer (EORTC) 62024 randomized patients 
with intermediate and high-risk GIST, based on size criteria 
and mitotic index as defined by Fletcher and colleagues,9 
to 2 years of adjuvant imatinib versus observation, while 
the Scandinavian Sarcoma Group (SSG) Trial XVIII ran-
domized patients with pathological and/or surgical (tumor 
spillage and microscopic margins positive) high-risk disease 
to 1 versus 3 years of adjuvant imatinib. Results of both 
studies may add valuable information to the optimal dura-
tion of adjuvant imatinib and refine patient selection criteria 
for such a therapeutic approach.
Role of imatinib in metastatic GIST
Prior to the use of tyrosine kinase inhibitors in GIST, the 
primary modality for treatment of localized and recurrent 
disease was surgical resection. Response rates to conven-
tional cytotoxics were 10% and patients were typically 
managed with repeated surgical resections. As described 
above, the vast majority of GISTs are defined by mutations 
in KIT, which lead to constitutive ligand-independent activa-
tion of the KIT-RTK, and subsequent downstream signaling 
resulting in uncontrolled cell growth.
Imatinib is a selective tyrosine kinase inhibitor which 
binds KIT, Bcr-Abl, PDGFA/PDGFB. In vitro data dem-
onstrated that imatinib inhibited downstream phosphoryla-
tion in GIST leading to interruption of cell proliferation.20 
Because of this data, imatinib (formerly known as STI571) 
was evaluated clinically in GIST in a heavily pre-treated 
patient.21 The patient experienced a dramatic response, 
supporting the rationale use of imatinib in this disease. 
A multi-center randomized phase II trial was performed in 
patients with advanced GIST. In this study, 147 patients with 
metastatic and/or unresectable GIST participated and were 
randomly assigned to 400 mg or 600 mg of imatinib per day. 
Despite the rarity of GIST and aided by a uniform diagnosis 
of KIT-positivity, accrual was completed in under 9 months. 
Overall, 54% of patients experienced a partial response and 
28% had stable disease. The median time to an objective 
response was 13 weeks. There was no complete response and 
14% of patients demonstrated evidence of early resistance to 
imatinib. Treatment was well tolerated and significantly, there 
was no difference in either response rates or toxicity between 
the two doses studied.17 In a recent update of this landmark 
study, 68% of patients experienced objective responses, 
including 2 patients with complete responses. Sixteen 
percent had prolonged disease stability and 12% exhibited 
progression. Notably, the median time to response in patients 
who achieved at least a partial response was 2.7 months 
and a quarter of these patients took more than 5 months 
to achieve their responses. At the time of disease progres-
sion dose escalation to either 600 mg/day or 800 mg/day 
provided tumor control rates of 26% (16% partial response 
and 9% stable disease) and 15% (8% partial response and 
8% stable disease) in the 400 mg/day and 600 mg/day arms 
respectively. The median time to progression and overall 
survival for the entire study cohort was 24 months and 
57 months respectively. There was no difference in time to 
progression or overall survival between the two imatinib dose 
levels. Of note, overall survival was equivalent in patients 
who achieved stable disease or partial response and as a 
group was superior to patients who had initial progression 
to imatinib, estimated 5-year survival rate of 55% versus 
9% respectively.22 This landmark study confirmed the 
efficacy and tolerability of imatinib in GIST and led to the 
approval of imatinib in patients with metastatic GIST by 
the FDA in 2002.
Impact of imatinib dose on patient 
outcome
Two large phase III international studies were performed to 
evaluate the impact of dose of imatinib on outcome. The first was 
an EORTC-led international effort involving 946 patients from 
Europe, Australia and Asia, randomly assigned to imatinib 
400 mg either once or twice daily (800 mg/day total dose). 
Patients randomized to the 400 mg/day arm were allowed 
to cross over to the 800 mg/day arm at time of disease 
progression. Grade 3–4 toxicities were more common 
on the higher dose arm (32% versus 50% respectively). 
In addition dose reductions and interruptions were more 
common on the higher dose arm. Overall objective response 
rates were 52% (5% complete and 47% partial), 32% had 
stable disease, with no significant differences between 
the two treatment groups when the entire cohort was 
analyzed. The high-dose arm did however experience a Biologics: Targets & Therapy 2010:4 23
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significantly longer median progression-free survival.23 In 
a follow-up analysis undertaken by Zalcberg and colleagues 
evaluating outcomes of patients who initiated imatinib at 
400 mg/day who crossed over to 800 mg/day at time of 
disease progression, tumor control could be re-gained in 29% 
of patients (2% partial and 27% stable disease), with a median 
progression-free survival of under 3 months.24 Concurrent 
to the EORTC study, a North American trial randomized 
746 patients with advanced GIST to standard (400 mg/day) 
versus high-dose (800 mg/day) imatinib. Median follow-
up was 4.5 years. Tumor responses were identical in both 
groups and there was no statistically significant difference 
in median progression-free 18 months versus 20 months and 
overall survival, and 55 months versus 51 months. A third 
of patients, on the standard-dose arm, who progressed and 
crossed over to the high-dose arm managed to re-gain tumor 
control, and achieved a median progression-free survival of 
5 months, closely replicating results from the EORTC study. 
Similar to the EORTC experience, serious adverse events 
were more common in the high-dose arm.25 In a pooled meta-
analysis of these two studies performed by Van Glabbeke 
et al, a small but statistically significant progression-free 
survival benefit was noted in the high-dose arm, approxi-
mately 19 months versus 23 months, with results consistent 
across both studies but significant only in the EORTC study. 
Overall survival was identical in both arms.26
Response evaluation in GIST
One of the clinical challenges in the development of 
imatinib in GIST was the difficulty in defining best meth-
odologies to evaluate this disease while patients are on 
treatment. Although PET scans demonstrated early and 
sustained metabolic responses in most patients, this was not 
always accompanied by objective responses per RECIST 
size criteria. Tumor shrinkage may take place many months 
after initiation of drug despite clinical improvement.17 
Work by investigators in MD Anderson Cancer Center 
comparing pre- and 2-month post-imatinib treatment scans 
from GIST patients found that a tumor decrease of more 
than 10% or a decrease in tumor density of 15% on CT 
was both sensitive and specific in identifying patients with 
good metabolic response. Based on these new CT imag-
ing criteria (termed Choi criteria), one is able to identify 
a cohort of patients with a longer time to progression.27 
These results were validated in an independent data set 
demonstrating that Choi response was superior to RECIST 
response in predicting time to progression and disease-
specific survival.28
Duration of imatinib therapy
In all the pivotal trials involving imatinib in advanced 
GIST, imatinib was continued until disease progression or 
emergence of prohibitive toxicities. Recently, the French 
Sarcoma Group evaluated the impact of dose interruption 
of imatinib in patients with advanced GIST. BFR14 is a 
phase III clinical trial randomizing patients with advanced 
GIST who achieved disease control on imatinib for at least 
1 year, to either treatment interruption versus continuation 
of imatinib.29 Fifty-eight patients were eligible and random-
ized into the two study arms. Significantly more patients 
in the imatinib-interrupted arm (81%) experienced disease 
relapse as compared to those on maintenance therapy 
(31%). Median progression-free survival was 6 months 
in the imatinib-interrupted arm versus 18 months in the 
maintenance arm. Twenty-four (92%) of the 26 patients 
with documented progression in the imatinib-interrupted 
arm responded to imatinib re-introduction, one progressed, 
and one died from a cerebral infarction before evaluation. 
An important issue arising from this study was whether dose 
interruption had a negative impact on incidence of subse-
quent imatinib resistance. On longer follow-up, 8 (25%) 
of the 32 patients randomized to the imatinib-interrupted 
arm progressed after imatinib re-introduction, compared 
to 8 (31%) of the 26 patients in the maintenance arm (first 
evidence of progression). This difference was not statisti-
cally significant and overall survival was virtually identical 
in both arms.
Impact of genotype on therapeutics
Shortly after the demonstration of imatinib efficacy in metastatic 
GIST, research efforts were focused on the molecular heteroge-
neity and impact of genotypic variations on clinical outcomes. 
It is now appreciated that 85% to 90% of all GISTs harbor 
activating mutations in either KIT or PDGFRA. As shown in 
Figure 2, the majority of these mutations occur in  KIT; exon 
11 (66%) being most commonly affected followed by exon 9 
(13%), with low incidences in exon 13 and 17 (about 1% each). 
Mutations in PDGFRA represent less than 10% of all mutations 
with exon 18 mutations (about 6%) being more common than 
exon 12 mutations (about 2%). The remainder of GISTs (12%) 
are wild-type for both KIT and PDGFRA.30 Tumor genotype 
has a major influence on clinical outcomes in the setting of ima-
tinib therapy. In one of the earliest studies correlating genotype 
to clinical response, using tumor tissue available from 127 of 
147 patients enrolled on the North American phase II trial of 
imatinib in patients with advanced GIST, partial response rate 
in patients with tumors that harbor exon 11 KIT mutation was Biologics: Targets & Therapy 2010:4 24
Quek and George Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
significantly superior to those patients whose tumors harbor 
exon 9 KIT mutation and wild-type GIST, 84% versus 48% 
respectively. In addition, progression-free and overall survival 
was superior in patients with exon 11 mutation.31 Similar 
findings were reported in the larger phase III studies evaluating 
standard and high dose imatinib. In the North American study, 
the presence of tumor KIT exon 11 mutation correlated with 
an improved objective response rate to imatinib (72%, 44%, 
45% respectively), time to progression (median 25 months, 
17 months and 13 months respectively) and overall survival 
(median 60 months, 38 months and 49 months respectively) 
when compared to patients with KIT exon 9 mutation and 
wild-type GIST. Additionally no significant differences were 
detected between KIT exon 9 mutants and wild-type GIST.32 
Likewise in the EORTC-led study, of 946 patients randomized 
to treatment, 377 had adequate tumor material for mutational 
analysis. When compared with patients whose tumors harbor 
exon 11 mutants, presence of exon 9 mutations and wild-
type GIST were the strongest adverse prognostic factor for 
objective response, risk of progression and death.33 Having 
identified a “high-risk” cohort of patients, investigators 
next questioned if imatinib dose-escalation could overcome 
this adverse prognostic feature. In the meta-analysis of the 
two large phase III imatinib dose-efficacy studies undertaken 
by Van Glabbeke and colleagues, a statistically significantly 
progression-free survival benefit in patients who received 
imatinib 800 mg/day was demonstrated in the subset of 
patients with KIT exon 9 mutations from EORTC dataset. 
This finding was not confirmed in the North American dataset. 
However, the benefit of imatinib 800 mg/day remained 
significant in the pooled dataset, median progression-free 
survival of 6 months versus 19 months, in the standard-dose 
and high-dose imatinib arms respectively, for patients whose 
tumors harbor exon 9 mutations.26,32,33 This finding may 
account for the improved overall progression-free survival 
seen in the EORTC study attributed to high-dose imatinib, 
where a larger proportion of KIT exon 9 mutants were enrolled 
(15% of analyzed patients in the EORTC study versus 8% 
in the North American study).
Role of imatinib trough levels
More recently plasma imatinib trough levels have been found 
to correlate with improved outcomes in patients with chronic 
myeloid leukemia (CML), another imatinib-sensitive disease, 
suggesting a trough threshold value of about 1000 ng/mL.34,35 
Imatinib is orally administered with good oral bioavailability. 
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Figure 2 Structure of KiT and PDGFrA. The location and relative frequencies of GiST-associated kinase mutations are depicted in relation to the structural features of KiT 
and PDGFrA.   The remainder of GiST (about 12% in this series) do not harbor detectable KIT or PDGFRA mutations.
Adapted with permission. © 2004 American Society of Clinical Oncology.   All right reserved. Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors.  J Clin 
Oncol. 2004;22(18):3813–3825.30 Adapted with permission. © 2003 American Society of Clinical Oncology. All right reserved. Heinrich MC, Corless CL, Demetri GD, et al. 
Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.  J Clin Oncol. 2003;21(23):4342–4349.31Biologics: Targets & Therapy 2010:4 25
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It is extensively bound to plasma proteins and is thought to be 
predominantly metabolized by CYP3A4 to an active metabolite 
CGP74588.11 Imatinib pharmacokinetic exposure demonstrates 
wide inter-patient variability34–36 and it is well documented that 
treatment-related toxicities are frequently dose-related.23,25 
Recently, imatinib trough levels taken from patients enrolled 
in the pivotal phase II GIST trial were correlated with patient 
outcome. In this study by Demetri and colleagues, 73 patients 
had imatinib trough samples collected for pharmacokinetic 
analysis. Pharmacokinetic exposure showed wide inter-patient 
variability, consistent with previous reports. Interestingly 
progression-free survival appeared to be associated with 
imatinib trough levels. Although the median imatinib trough 
levels of responding patients (a composite end-point defined 
as objective response plus stable disease) was numerically 
superior to non-responding patients, 1446 ng/mL (range, 414 to 
3336 ng/mL) versus 1155 ng/ml (range, 545 to 4182 ng/mL), 
the drug exposure ranges were wide with considerable overlap 
and were not statistically significant. However, patients in the 
lowest imatinib trough quartile, corresponding to a threshold 
value of 1110 ng/mL, was significantly correlated with a short-
ened time to disease progression 11.3 months versus 30 months, 
when compared to those in quartiles 2 to 4.36 Interestingly, 
there was no significant difference between quartiles 2, 3, 
and 4. Additional research is needed to prospectively confirm 
these exploratory results, as well as evaluate clinical factors 
which may impact trough level as well as outcome.
Therapeutic options following 
progression on imatinib
Median time to progression on first-line imatinib is approxi-
mately 2½ years. Fifteen percent of patients are primarily 
refractory to imatinib while the majority of patients who fail 
imatinib do so after a period of disease control (secondary 
failure). Patterns of failure can be classified into progression 
in a limited fashion, involving a small number of new tumor 
nodules and/or progressive lesion in some of the existing 
tumors, or a more generalized pattern of failure. Studies have 
consistently shown secondary kinase mutations to be the most 
common mechanism of imatinib resistance.37–39 A unique pat-
tern of GIST progression has been reported whereby a resis-
tant clonal nodule develops within a pre-existing tumor mass. 
In this setting, of note, molecular studies have demonstrated 
the presence of new kinase mutations in 80% of cases.40
Metastacectomy in the TKI era
In the pre-TKI era, metastacectomy was routinely recom-
mended in patients with metastatic GIST especially those 
with limited metastases or where complete surgical resection 
was possible. Whether this remains to be true in the TKI era 
is an area of active investigation. Current literature on this 
topic is retrospective in nature and prospective randomized 
clinical trials are under development to address this clinical 
question. Raut and colleagues retrospectively evaluated the 
outcome of 69 consecutive patients with primary unresectable 
or metastatic GIST, who underwent surgery while receiving 
TKI.41 Complete surgical resection was attempted whenever 
possible. Patients were categorized based on response to TKI 
at the time of surgery (stable disease which included patients 
initially with unresectable or metastatic GIST who achieved 
a drug response to render all disease resectable and whose 
tumors were not growing at the time of surgery, limited disease 
progression or generalized disease progression) and surgical 
result (no evidence of disease, minimal residual disease or 
bulky residual disease). Results of this single center study sug-
gested that response to TKI was significantly associated with 
surgical outcome. Seventy-eight percent of patients with stable 
disease at the time of surgery were rendered radiographically 
disease-free post-operatively, as compared to 25% and 7% of 
patients with limited progression and generalized progression 
respectively. Conversely bulky residual disease remained after 
surgery in 4%, 16%, and 43% of these patients respectively. 
One-year progression-free survival in patients with stable dis-
ease, limited progression and generalized progression was 80%, 
33%, and 0%. The median time to progression for patients with 
limited and generalized disease progression was 7.7 months and 
2.9 months respectively, while the median time to progression 
for patients with stable disease has not been reached after a 
median follow-up of 14.6 months (range, 0.5 to 36.4 months). 
One-year overall survival was 95%, 86%, 0% respectively. The 
authors concluded that patients with advanced GISTs exhibiting 
stable disease or limited progression on TKI have prolonged 
survival after debulking procedures while surgery has little to 
offer in the setting of generalized progression. While it is clear 
that patients with generalized disease progression are unlikely 
to benefit from surgery, it is unclear from this study whether 
the improved progression-free and overall survival seen in 
patients with stable disease and limited disease progression 
was a result of surgical intervention or inherent tumor biology 
and response to TKI.
Sunitinib
Sunitinib malate (Sutent®; Pfizer) is a multi-targeted small 
molecule TKI with activity active against KIT, PDGFR, all 
3 isoforms of vascular endothelial growth factor receptors 
(VEGFR), FLT3, and RET. Due to this spectrum of inhibition, Biologics: Targets & Therapy 2010:4 26
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it has both antiproliferative and antiangiogenic properties 
and was felt to be a rational choice for evaluation in patients 
with imatinib-resistant GIST. Following promising results 
from a phase I/II trial, a large, international, phase III, 
randomized, placebo-controlled trial was undertaken in 
patients with imatinib-resistant or imatinib-intolerant GIST. 
Three hundred and twelve patients were randomized in a 2:1 
ratio to either sunitinib 50 mg daily, in a 4-weeks-on and 
2-weeks-off regimen, or placebo.42 The primary end-point 
was time to progression in an intention-to-treat analysis. 
The study was unblinded early when an interim analysis 
revealed significantly longer time to progression in the 
sunitinib arm, approximately 6.8 months versus 1.6 months 
in the placebo arm. Treatment was fairly well tolerated with 
serious treatment-related toxicities reported in 20% and 5% 
sunitinib- and placebo-treated patients respectively. Common 
adverse events include fatigue, diarrhea, hand-foot syndrome, 
hypertension, and skin discoloration. Based on the results of 
this study, sunitinib was approved by the FDA for treatment 
of imatinib-resistant or intolerant advanced GIST.
Although sunitinib, given in the intermittent dosing sched-
ule, clearly has benefit in this patient population, earlier clinical 
trials demonstrated a metabolic “flare” as defined by an increase 
in activity of 18FDG-PET, during the 2-week rest period. When 
patients were followed by  18FDG-PET, metabolic response 
was noted as early as 7 days post-initiation of therapy, but this 
suppression was followed by a rebound during the 2-week-off 
period, suggesting a flare in disease activity, consistent with lack 
of TK inhibition during the wash-out period.43 In an attempt to 
provide consistent TK inhibition, and to enhance convenience 
of dosing, an international, multicenter phase II study using 
continuous daily dosing of sunitinib, at 37.5 mg/day, was under-
taken to examine this issue.44 In this study, sixty-one patients 
with advanced GIST following imatinib failure were enrolled. 
Clinical benefit was observed in 53% of patients (defined as 
RECIST complete or partial response or stable disease lasting 
24 weeks or longer), including a 13% partial response rate. 
The median progression-free survival was 8.5 months. Toxicity 
assessment yielded no new safety concerns and was similar 
to intermittent dosing schedule, which included diarrhea, 
abdominal pain and asthenia. Pharmacokinetic evaluations 
demonstrated sunitinib continuous daily dosing achieved 
constant drug exposure with no unexpected accumulation.
Mechanisms of resistance 
to tyrosine kinase inhibitors
Imatinib resistance can be divided into primary resistance 
(defined as progressive disease as best response) and 
secondary resistance (disease progression after a period of 
objective response or stable disease). Preclinical data demon-
strate that KIT kinase is inhibited in patients with imatinib-
responsive GIST but reactivation of KIT and subsequent 
downstream phosphorylation occurs at the time of secondary 
resistance. In contrast, KIT signaling in primary imatinib-
resistant GIST shows no evidence of inhibition to imatinib 
and is similar to that seen in untreated GIST, indicating that 
KIT primary resistance is associated with persistent KIT 
phosphorylation and activation of downstream pathways.37 
The molecular mechanisms responsible for primary-imatinib 
resistance differ from those of secondary resistance. KIT 
exon 9 and PDGFRA mutations more commonly demonstrate 
primary-imatinib resistance when compared to KIT exon 11 
mutations. The underlying mechanisms responsible for this 
resistance may be secondary to differences in the structure 
of the ATP-binding loop and the relative affinity of imatinib. 
Phase III studies demonstrating higher dose of imatinib 
correlating with a progression-free survival in the subset of 
KIT exon 9 mutants would suggest an inherent decreased 
drug sensitivity, which may potentially be overcome by 
imatinib dose escalation.26 The predominant mechanism by 
which GIST cells develop secondary-imatinib resistance is 
through the acquisition of secondary kinase mutations. This 
phenomenon is more commonly observed in primary KIT 
exon 11 mutant GISTs.37,39,45 In contrast, patients with pri-
mary imatinib-resistant GIST rarely harbor secondary kinase 
mutations, 10% versus 67% in those with primary versus 
secondary resistance respectively.37 These secondary muta-
tions are non-random in distribution and cluster around KIT 
exon 13/14 (which encodes the ATP-drug binding pocket) 
and exon 17/18 (which encodes kinase activation loop) and 
are associated with decreased imatinib sensitivity, confirmed 
in in vitro models.37,39,45 Additionally these secondary kinase 
mutations also impact on clinical outcomes in second-line 
sunitinib treatment. In a report by Heinrich and colleagues, 
examining a large cohort of imatinib-refractory patients 
uniformly treated with sunitinib, patients with secondary 
KIT exon 13/14 mutations had significantly improved clinical 
benefit (objective response and stable disease  6 months) 
and survival outcomes than those with secondary KIT exon 
17/18 mutations.45 Structural and enzymologic reasons could 
in part explain the resistance to sunitinib consequent to sec-
ondary mutations in the kinase activation loop.46
Pediatric GIST
GIST in the pediatric age group is rare, accounting for less 
than 1% to 2% of all GIST cases.47 Although pediatric GISTs Biologics: Targets & Therapy 2010:4 27
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express KIT and display a high level of KIT activation, unique 
differences exist that distinguish them from adult GISTs, 
notably, the relative absence of KIT or PDGFRA mutations, 
with only less than 15% of cases harboring these mutations.3–4 
In contrast, activating mutations in KIT or PDGFRA are 
found in more than 85% of adult GISTs.30 Recent reports 
suggest pediatric GISTs exhibit distinct gene-expression 
signatures4 and genetic progression mechanisms from adult 
GISTs.3 Consistent with the molecular profile of wild-type 
GISTs, most pediatric GIST cases respond less favorably 
to imatinib than adult KIT exon 11 mutant GISTs. In vitro 
studies suggest sunitinib and other TKIs including nilotinib 
(Tasigna®; Novartis Oncology), dasatinib (Sprycel®; Bristol-
Myers Squibb) and sorafenib (Nexavar®; Bayer HealthCare 
Pharmaceuticals–Onyx Pharmaceuticals) may be more active 
than imatinib against wild-type GIST.4 A series published 
by Janeway and colleagues reported 7 imatinib-refractory 
pediatric patients (age range 10 to 17) with advanced GIST 
treated with sunitinib. Five patients had sufficient tumor 
for genotyping, and were KIT or PDGFRA wild-type. Prior 
to sunitinib, three of the 6 patients treated with imatinib 
(one received adjuvant imatinib following tumor resection 
and experienced disease recurrence while on therapy) had 
progressive disease as best response while the remaining 
3 had stable disease lasting between 12 to 16 months. 
On sunitinib, 1 patient achieved a partial response with time 
to progression lasting more than 21 months, 5 patients had 
stable disease, and 1 had progressive disease. The duration of 
disease stabilization ranged from 7 to more than 21 months 
with a mean of 15 months, suggesting that sunitinib may 
have activity in this unique subset of GISTs.48
More recently reports have shown insulin-like growth 
factor-1 receptor (IGF-1R) to be strongly over-expressed in both 
adult and pediatric wild-type GIST.49,50 IGF-1R amplification is 
also detected at a higher frequency in wild-type as compared 
to kinase-mutant GIST49 and aberrant IGF-1R expression may 
be associated with pathogenesis of wild-type GISTs. Further 
studies are needed to determine if inhibition of the IGF-1R 
pathway is relevant to clinical outcomes in these patients. 
Also, recent reports have suggested that a small percentage of 
patients with KIT and PDGFR wildtype GIST may harbor an 
activating mutation in BRAF.51 These findings highlight the 
heterogeneity of these tumors on a molecular level which may 
ultimately lead to more personalized treatment strategies.
Familial GIST
Heritable mutations in KIT and PDGFRA, likely of auto-
somal dominant inheritance pattern, have been reported 
in the literature.52–54 Affected kindreds with familial GIST 
may present with multi-focal disease, and in some cases 
associated with cutaneous and mucous membrane hyper-
pigmentation, urticaria pigmentosa, mast cell disease and 
diffuse spindle cell hyperplasia in the myenteric plexus of 
the gastrointestinal tract. Carney’s triad is a rare and possibly 
familial tumor syndrome.55 It predominantly affects young 
women and comprises of gastric stromal sarcoma (GIST), 
pulmonary chrondroma and extra-adrenal paraganglioma. 
Neurofibromatosis type 1 (NF-1) has also been associated 
with development of GIST. In a population-based study of 
70 patients with NF-1 conducted in Sweden, 7% of patients 
were diagnosed with GIST.56 These NF-1 associated GISTs 
are frequently multi-focal, often affecting the small bowel, 
and are typically KIT/PDGFRA mutation negative.57
Strategies in imatinib-  
and sunitinib-resistant GIST
As mentioned above, imatinib has revolutionized the 
management of advanced GIST. Resistance however does 
develop in the majority of patients and the management of 
imatinib-resistant GIST remains a challenge. Dose escala-
tion of imatinib may be supported for patients treated at 
400 mg/day. However, responses to dose escalation tend 
to be relatively short-lived. Because of this there has been 
tremendous interest in strategies to manage imatinib-resistant 
GIST. Sunitinib, is currently the only FDA-approved therapy 
for patients with imatinib-resistant GIST. However, as with 
imatinib, resistance to sunitinib ultimately develops in most 
patients. Because of this, there remains intense interest in 
additional approaches to this disease.
A wide range of newer and more potent small molecule 
TKI that target KIT and/or PDGRA are in development. 
An agent with interesting single agent activity is sorafenib. 
Sorafenib is a multi-targeted small molecule TKI with potent 
activity against B-RAF tyrosine kinase, VEGFR, PDGFR, 
KIT, and FLT3 recently approved for use in patients with 
renal cell and hepatocellar carcinoma. In a phase II efficacy 
study carried out by the University of Chicago consortium, 
26 patients with imatinib (6 patients) and sunitinib-resis-
tant GIST (20 patients) were enrolled and treated with 
sorafenib 400 mg twice daily. Three (13%) and 14 (58%) 
out of 24 patients evaluable for response exhibited partial 
response and stable disease respectively, for a disease control 
rate of 71%. The median progression-free survival was 
5.3 months.58 These results were supported by the recently 
reported European experience with sorafenib in this same 
patient population. In this retrospective study, thirty-two Biologics: Targets & Therapy 2010:4 28
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heavily pre-treated patients who failed imatinib, sunitinib and 
nilotinib were treated with sorafenib in the 4th-line setting. 
Nineteen percent of patients achieved a partial remission 
and 44% had disease stabilization. Median progression-free 
survival was 20 weeks and median overall survival was 
42 weeks.59 These findings were corroborated in cell line 
models studying the in vitro activity of sorafenib against 
imatinib and/sunitinib-resistant kinases. The predominant 
mechanism of imatinib resistance is through the acquisition 
of secondary kinases as described. Sorafenib demonstrated 
significant activity in imatinib-resistant KIT secondary muta-
tions involving the ATP-binding pocket and activation loop. 
And notably, sorafenib unlike sunitinib is active against most 
imatinib-resistant secondary mutations involving the KIT 
activation loop.60 As the majority of patients in these studies 
had failed both imatinib and sunitinib, these results suggest 
that sorafenib may have promising activity in the treatment 
of GIST following imatinib and sunitinib failure.
Nilotinib is a second generation small molecule TKI 
with good activity against receptors of KIT and PDGFR. 
In a dose-finding phase I study, 53 GIST patients resistant 
to imatinib and other TKIs, were enrolled and treated with 
nilotinib alone (18 patients) or in combination with imatinib 
(35 patients). Although not designed as an efficacy study, 
one patient on single agent nilotinib had a partial response 
while 13 others had stable disease for a disease control rate 
of 78% a median progression-free survival of 5.6 months.61 
Clinical trials are currently ongoing evaluating the benefit 
of nilotinib in the third line setting.
Similarly masitinib with reportedly greater affinity and 
selectivity for both the wild-type and mutated KIT than 
imatinib was investigated in a phase I dose-escalation study 
in patients with advanced and/or metastatic cancer. Half 
of the enrolled cohort had GIST. Treatment was gener-
ally well tolerated and the maximally tolerated dose was 
not determined in this study. One of 2 imatinib-intolerant 
patients demonstrated a partial response and about 29% of 
imatinib-resistant patients had stable disease.62 Building on 
these results, a multi-center phase II study of masitinib in 
treatment-naïve GIST patients led by the French Sarcoma 
Group was initiated. In a preliminary report 50% of patients 
demonstrated objective partial response (6.7% complete and 
43.3% partial response), 47% had stable disease and 3% were 
primarily refractory to masitinib, yielding a overall disease 
control rate of 97%. The median progression-free survival 
was 27 months, comparable with imatinib.63 Phase III studies 
comparing nilotinib and masitinib as single agents with 
imatinib in the first line setting are now underway.
As discussed above there is substantial heterogeneity in 
the secondary mutations which render GIST resistant to TKIs. 
In addition, there may be pathways and strategies other than 
direct KIT inhibition, which are relevant to the biology of 
these tumors. Because of this, research efforts are focused 
on strategies which may be relevant in this disease other than 
direct KIT inhibition.
Heat shock protein-90 (HSP90) is an ATP-dependent 
protein chaperone involved in the regulation of cellular 
protein homeostasis. It regulates the stability of key proteins, 
including the KIT oncoproteins, important in oncogenesis, 
cancer cell proliferation, and cancer cell survival and plays 
a central role in protein folding in response to various envi-
ronmental stresses.64 Pre-clinical work involving cell line 
models using 17-allylamino-18-demethoxy-geldanamycin 
(17-AAG), an inhibitor of the HSP90 chaperone protein, 
demonstrated significant reduction of both phospho- and 
total KIT expression, inactivation of downstream signaling 
pathways and inhibition of cellular proliferation and survival 
in both imatinib-sensitive and imatinib-resistant KIT-positive 
cell lines. Similar activity could not be demonstrated in 
a KIT-negative cell line suggesting that HSP90 inhibitor 
exerts its therapeutic function through its actions on KIT 
oncoprotein.65 Based on this preclinical rationale, a phase I/II 
study was conducted using IPI-504 (Retaspimycin Hydro-
chloride; Infinity Pharmaceuticals) in patients with metastatic, 
TKI-resistant GIST or metastatic soft tissue sarcoma.66 In the 
subset of 38 GIST patients, treatment was well tolerated; 
dose-limiting toxicities were headache and myalgia. Of the 
18 GIST patients assessed by PET, 22% had a partial 
response and an additional 66% had stable disease accord-
ing to the EORTC PET response criteria.67 Although no 
RECIST-defined responses were observed, approximately 
three-quarters of evaluable patients had stable disease as 
best response. This led to the initiation of an international 
phase III study in GIST. However the trial was closed early 
at the recommendation of an independent data monitoring 
committee due to safety concerns. Trials are now underway 
evaluating other HSP90 inhibitors in GIST. Additionally, 
in preclinical studies, PI3-kinase/mTOR pathways appear to 
be important in cell signaling and proliferation not only in 
imatinib-resistant cell lines but also in imatinib-sensitive and 
KIT-negative GIST.68 A number of PI3-kinase inhibitors and 
dual PI3-kinase/mTOR inhibitors are now in development 
and may prove to be effective in TKI-refractory GIST.
Combining agents that possess non-lapping toxicities 
targeting different aspects of the GIST cancer pathway 
in a synergistic fashion is another rationale approach to Biologics: Targets & Therapy 2010:4 29
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development of novel therapeutics. Based on in vitro 
synergism demonstrated between imatinib and everolimus 
(previously known as RADOO1; Novartis Oncology) in 
human imatinib-resistant GIST cell lines, phase I/II clinical 
studies combining the 2 agents were performed. Primary 
study end point, defined as 4-month progression-free 
survival, was achieved in 17% (imatinib-refractory) and 
37% (imatinib plus additional therapy) of patients prompt-
ing further studies into the various strategies of combined 
tyrosine kinase and mTOR inhibition.69
Conclusions
In the decade following the landmark discovery of activat-
ing KIT mutation in GIST, much has been learned about this 
disease. A further understanding of the biology and molecular 
genetics of GIST, has translated into rationale approaches to 
clinical care. Through extensive international collaborations, 
large studies in this uncommon disease have first confirmed 
activity of imatinib in treatment-naïve patients and then 
sunitinib in the second line setting. Significant inroads have 
also been made into understanding the mechanisms of TKI 
resistance and molecular heterogeneity at disease progres-
sion which should lead to effective therapeutic strategies for 
patients in the future.
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